"1 Earnings Call Transcript Summary

Labcorp reported strong results in the third quarter of 2021, with revenue totaling $4.1 billion, adjusted earnings per share reaching $6.82, and free cash flow of $650 million. The company's Diagnostics and Drug Development businesses performed well, with 10% and 22% growth, respectively. COVID testing volumes were higher than anticipated, with time to results averaging one to two days. Labcorp has been supporting the fight against the pandemic through both its diagnostic and drug development capabilities. The company is currently working on several COVID-related projects, including a prevention and treatment trial with AstraZeneca and an oral antiviral medicine from Merck. Labcorp is also integrating OmniSeq, a leading pan-cancer diagnostic capabilities, and launched clonoSEQ, the first and only FDA-cleared test for monitoring residual blood cancer. The company expects to drive continued profitable growth in its Base Business while COVID testing volumes are expected to decline through the remainder of the year. Labcorp plans to use its free cash flow generation for acquisitions that"
